# NNF

NNF is an Asset Manager based in New Canaan, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New Canaan, United States
- **Region:** North America
- **Address:** 27 Pine Street-Suite 600, New Canaan, CT 06840, United States
- **Assets under management:** Undisclosed
- **Website:** neuronetworksfund.org
- **LinkedIn:** https://www.linkedin.com/company/nnf

## Regulatory record

- **Reports private funds:** No

## About

NNF focuses on accelerating time to market for drugs, diagnostics and other medical products for patients with serious neurological disorders including autism, epilepsy and schizophrenia. It identifies new products, therapeutics or diagnostics and invests in or forms companies that translate research into products, bridging the gap so they become attractive to later-stage VCs and Pharma. As a not-for-profit organization, all investment returns are reinvested to support additional projects.

## Sectors

- Digital Health
- Healthcare Services

## People

- Sandra Panem — PhD (Executive)
- Brian Horsburgh — PhD (Executive)
- Tierney Saccavino-Payne (Executive)
- George Saussy (Executive)
- Peder Jensen — MD (Board of Trustees)
- Jane Jablons (Board of Trustees)
- Marina Bozilenko (Board of Trustees)
- Michele Kong — MD (Board of Trustees)
- Richard J. Resnick — M.S., M.B.A. (Board of Trustees)
- Richard Whitley — MD (Scientific Advisory Board)
- Kevin Pelphrey — PhD (Scientific Advisory Board)
- Deborah Hirtz — MD (Scientific Advisory Board)
- Anika Heavner (Business Advisory Board)
- Libby Mullen (Social Media)

## Questions

### How does NNF fund its investments?

NNF is a 501(c)(3) non-profit organization, so it relies on tax-deductible donations to fund its investment activities. All contributions are reinvested to support additional projects and novel research. The firm does not operate with a traditional limited partner fund structure or charge management fees.

### What types of investments does NNF make?

The firm makes direct investments in companies and project-level financing for single assets. Its investing includes traditional biotech start-ups and platform technology companies. NNF does not publicly disclose a portfolio, but its mandate targets products for neurological disorders like autism, epilepsy, and schizophrenia.

### Who runs investment decisions at NNF?

NNF's website lists an Executive team, Board of Trustees, Scientific Advisory Board, and Business Advisory Board, but does not publicly name specific executives or investment decision-makers. Without disclosed principals, the precise delegation of investment authority is not verifiable from current public sources.

### How is NNF related to traditional venture capital firms?

NNF explicitly positions itself to fill a gap left by disappearing early-stage biotech venture capital firms. It works to make companies attractive to later-stage VCs and pharmaceutical companies by providing initial funding and hands-on management, but it operates as a mission-driven non-profit rather than a for-profit fund.

### What is NNF's investment stage focus?

NNF focuses on very early-stage translational research. It invests in or forms companies that are translating academic research into products, providing the initial capital and operational support that these projects need before they can attract later-stage venture or pharmaceutical investment.

## Related profiles

- [NN CDC Pensioenfonds](https://altss.com/profile/nn-cdc-pensioenfonds)
- [NNFE](https://altss.com/profile/nnfe)

---

Last updated: 2026-08-11T15:07:34.613Z

Canonical page: https://altss.com/profile/nnf

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology